【药明康德(02359.HK):计划受托人已完成2025年H股奖励信托计划项下合计25亿港元的H股股份购买】智通财经AP

智通财经
30 Jun
【药明康德(02359.HK):计划受托人已完成2025年H股奖励信托计划项下合计25亿港元的H股股份购买】智通财经APP讯,药明康德(02359.HK)公布公布,2025年6月13日至2025年6月27日,计划受托人根据公司指示通过市场内交易方式实施2025年H股奖励信托计划附加授予条件项下的H股股份购买,累计使用资金10亿港元,购买H股股份数为12,987,886股H股,占公司截至本公告日期已发行股本总额的约0.45%,前述购买H股股份将作为2025年H股奖励信托计划项下附加授予条件(即集团于2025年实现的营业收入达到人民币430亿元或以上)达成后向选定参与者授予奖励的股份来源。截至本公告日期,计划受托人已完成2025年H股奖励信托计划项下合计25亿港元的H股股份购买,该等H股股份将作为基本授予条件及附加授予条件项下授予奖励的股份来源。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10